Day: May 6, 2021

  – In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study.  – AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism.CHARLESTON, S.C., May 06, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that, in consultation with The University of Sheffield, UK (the “University”), Aeterna has selected AEZS-150 as the lead...

U.S. cybersecurity services firm adds NBA executive as director SCOTTSDALE, Ariz., May 06, 2021 (GLOBE NEWSWIRE) — Cerberus Cyber Sentinel Corporation (OTC: CISO) (“Cerberus Sentinel”), a cybersecurity consulting and managed services firm, announced today that E.M. “Kiki” VanDeWeghe III has been appointed to its board of directors. VanDeWeghe adds significant executive and management experience to Cerberus Sentinel’s board of directors. Currently, VanDeWeghe serves as executive vice president, basketball operations, for the National Basketball Association. In this role, he oversees all aspects of basketball related to the playing of the game, and he serves as a key liaison between the league office and its teams. He was a two-time NBA All-Star during his 13-year playing career, and he has previously served as general...

TAMPA, Fla., May 06, 2021 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ:LMFA) (“LM Funding” or “LMFA”), a technology-based specialty finance company, today announced a 1-for-5 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on May 7, 2021. Beginning tomorrow, May 7, 2021, LM Funding’s common stock will trade on a split-adjusted basis. At LM Funding’s Annual Meeting of Shareholders (the “Annual Meeting”) held on May 11, 2020, the Company’s shareholders approved a proposal to amend the Company’s Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio within the range of one-for-two (1:2) to one-for-ten (1:10), as determined by the Company’s Board of Directors. On April 21, 2021, the Board of Directors approved a 1-for-5 reverse...

EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”), today announced that it has completed recruitment for its Phase 2a ‘AMBITION’ clinical trial, with all NASH patients in the 225 mg CRV431 dosing cohort now enrolled. “Over the past few months, the COVID-19 pandemic, compounded by the inclement weather experienced at some of our clinical trial sites in Texas, which resulted in power outages, presented difficulties in the recruitment of subjects for the second and final dosing cohort for our Phase 2a NASH trial,” said Dr. Robert Foster, Hepion’s CEO. “However, we were able to overcome these challenges and...

Balstilimab BLA submitted to FDA for recurrent/metastatic cervical cancer Balstilimab and AGEN2373 data to be presented at ASCO iNKT cell therapy Phase 1 initiated in cancerLEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the first quarter of 2021. “We have delivered on multiple key initiatives since our last update and expect to achieve additional impactful milestones during the remainder of the second quarter and the rest of 2021,” said Garo Armen, PhD, Chief Executive Officer of Agenus. “Among important developments are the continuing clinical responses...

The Annual General Meeting of Norsk Hydro ASA was held on 6 May 2021. The meeting was conducted as a virtual meeting due to Covid-19. All proposals on the agenda were adopted, c.f. the notice of the Annual General Meeting that was published 13 April 2021, including the proposal to distribute a dividend of NOK 1.25 per share. The dividend will be paid on May 19, 2021 to ordinary shareholders as of May 6, and who are listed in the Norwegian Central Securities Depository as of May 10. The share will be traded ex-dividend from May 7. The minutes of the Annual General Meeting is attached and available on www.hydro.com/generalmeeting. Investor contacts Line Haugetraa +47 41406376 Line.Haugetraa@hydro.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachment...

ST. JOHN’S, Newfoundland and Labrador, May 06, 2021 (GLOBE NEWSWIRE) — Red Moon Resources Inc. (the “Company” or “Red Moon” – TSXV: RMK) announces that it has arranged a non-brokered private placement financing with strategic investors to raise total gross proceeds of up to $3.25 million. Mr. Patrick Laracy, Red Moon CEO, commented: “Our Great Atlantic Salt Project Feasibility Study is fully funded. As outlined in our April 27 news release, favorable dynamics have created new opportunities to expand our profitable gypsum operations. This financing with strategic investors will allow us to do that.” Under the terms of the offering, the Company intends to place 3,461,538 units at $0.65 per unit. Each unit will consist of one common share and one-half of a common share purchase warrant, with each whole warrant to be exercisable...

TORONTO, May 06, 2021 (GLOBE NEWSWIRE) — Ayurcann Holdings Corp. (CSE: AYUR) (the “Company” or “Ayurcann”), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to announce its newly formed Advisory Board consisting of cannabis and non-cannabis sector professionals, who will provide guidance relating to the Company’s strategic plans and initiatives, and highlight potential key areas of opportunity within the industry. Igal Sudman, CEO of Ayurcann, commented: “We are thrilled to be officially launching the Ayurcann Advisory Board. The Executive Team has taken several months carefully selecting this group of top professionals who each bring unique strengths and backgrounds to the Company. We are proud to say that we have selected these...

Šiaulių Bankas AB (hereinafter referred to as the Bank), company code 112025254, Tilžės st. 149, Šiauliai, Lithuania. During the Investor Conference Webinar Vytautas Sinius, CEO and Donatas Savickas, CFO introduced the Bank’s financial results for the Q1 of 2021 and recent developments and answered the participant questions aftewards. 91 participant had registered for the webinar, the recording of it can be found on Nasdaq youtube channel there. Presentation and the recording of webinar are also posted on the Bank’s website https://sb.lt/en/investors Šiaulių bankas thanks all participants. Additional information:Tomas VarenbergasHead of Treasury and Marketstomas.varenbergas@sb.lt, +370 5 203 22 00